Study looks at factors influencing African-American women's decisions to join cancer screening trial

December 01, 2005

PITTSBURGH, Dec. 1 - Do African-American women who join a screening trial for cancer differ from those who do not join? Researchers at the University of Pittsburgh's Graduate School of Public Health sought to answer this question by surveying African-American women who were invited to join the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, a randomized, community-based longitudinal study evaluating the effectiveness of cancer screening tests on site-specific mortality.

Their results, published in today's issue of the Journal of Clinical Oncology, indicate that African-American women who decided to join PLCO held significantly different beliefs regarding the benefits and risks of participation than those who did not join - the majority of those who joined were much more likely to report that African-Americans benefit as much as whites from participating in clinical trials. Interestingly, the study also found that none of the women surveyed had reported learning about clinical trials from their doctors or other health care providers.

"By interviewing women who joined the PLCO as well as those who did not, we were able to analyze their responses and suggest a strategy for improving the recruitment of African-American women to cancer clinical trials," said Jeanette Trauth, Ph.D., lead author of the study and associate professor of behavioral and community health sciences, University of Pittsburgh Graduate School of Public Health.

The researchers interviewed 299 African-American women between the ages of 55 and 74 who were eligible for the PLCO; 230 of these women decided not to participate in PLCO (non-joiners) and 69 of these women decided to participate in PLCO (joiners). The investigators found that joiners had a better understanding of cancer and the role of early detection and screening, and appeared to be motivated to join a trial by the experience of having a loved one with cancer. Joiners also tended to seek out information more than non-joiners and were willing to take the next step and take part in a study of a new treatment for a health problem that they perceived was important, especially if they or one of their loved ones had the problem.

Although there were differences between the groups, there also were similarities. The two groups had similar attitudes about cancer and their susceptibility to PLCO cancers. Most joiners and non-joiners alike, 73 and 72 percent respectively, agreed that if meant to get cancer, a woman would get it regardless of what she did to prevent it. However, they did not think having cancer was automatically a death sentence. The majority of both groups also reported that they would be unlikely to get lung, colon or ovarian cancer during their lifetimes.

One of the most striking findings was that none of the participants in the study reported their doctor had talked to them about joining a clinical trial. "This represents a major missed opportunity to impart vital educational information and to recruit African-American women more successfully into clinical trials," said Dr. Trauth.

To increase recruitment of African-American women to cancer clinical trials, Dr. Trauth suggests first providing women a health benefit that they want and need. She also suggests creating registries of African-American women interested in participating in clinical trials from current or former participants; informing physicians about the importance of talking to their patients about clinical trial opportunities; engaging African-American women in a dialogue about their perceptions of clinical trials; and providing them with the tools they need to make informed decisions.
The study was funded by a grant from the National Cancer Institute. Co-authors of the study include Jan Jernigan, Ph.D., Laura Siminoff, Ph.D., Donald Musa, Dr.PH., Derietra Neal-Ferguson, R.N., M.P.H., and Joel Weissfeld, M.D., M.P.H.

University of Pittsburgh Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to